Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) FCF Margin (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed FCF Margin for 15 consecutive years, with 49.32% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 3315068.0% to 49.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 139.24% through Dec 2025, up 1584647.0% year-over-year, with the annual reading at 139.5% for FY2025, 1584621.0% up from the prior year.
  • FCF Margin hit 49.32% in Q4 2025 for Guided Therapeutics, up from 461.67% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 258.33% in Q4 2021 to a low of 34800.0% in Q2 2021.
  • Historically, FCF Margin has averaged 7840.94% across 5 years, with a median of 1967.42% in 2023.
  • Biggest five-year swings in FCF Margin: plummeted -3215000bps in 2024 and later skyrocketed 3315068bps in 2025.
  • Year by year, FCF Margin stood at 258.33% in 2021, then plummeted by -7958bps to 20300.0% in 2022, then soared by 95bps to 1050.0% in 2023, then plummeted by -3062bps to 33200.0% in 2024, then soared by 100bps to 49.32% in 2025.
  • Business Quant data shows FCF Margin for GTHP at 49.32% in Q4 2025, 461.67% in Q3 2025, and 144.44% in Q2 2025.